« Return to News | Awards & Advancement

AMRI names business development director

Monday, June 17, 2013 02:00 PM

AMRI named Susan Collins director of business development for North American Discovery Services, reporting to Christopher Conway, vice president of business development. Collins is responsible for leading a team promoting AMRI's global drug discovery services.

With 19 years of pharmaceutical industry and leadership experience, Collins will manage business development activities and professionals and spearhead AMRI's efforts to expand discovery opportunities and business within the sector.

Collins has worked in sales and leadership positions at Organon BioSciences, which was later acquired by Schering-Plough and Merck. As region sales director, she was responsible for leading management and representative teams in the promotion of CNS, cardiovascular, anti-infective, anesthesia, pain management and contraceptive products to the medical community across 28 states. Directing teams of up to 125 employees, Collins was responsible for generating sales of more than $174 million with a $7.8 million operating budget.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.